CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Planned sale Director sold 1,666 shares at $18.37 ($30,604)
- 4 Open-market sale Director sold 2,750 shares at $17.29 ($47,548)
- 4 Open-market sale President and CEO sold 9,589 shares at $17.29 ($165,794)
- 4 Planned sale Chief Medical Officer sold 4,189 shares at an average $17.46 ($73,130)
- 4 Planned sale COFO and Secretary sold 22,844 shares at an average $17.62 ($402,420)
- 4 Option exercise COFO and Secretary acquired 50,000 shares (option exercise)
- 4 Planned sale Director sold 1,666 shares at $18.42 ($30,688)
- 4 Planned sale Chief Medical Officer sold 4,668 shares at $19.02 ($88,785)
- 4 Open-market sale President and CEO sold 7,818 shares at $19.78 ($154,640)
- 4 Open-market sale Chief Medical Officer sold 9,972 shares at $19.43 ($193,756)
- 4 Open-market sale Director sold 3,208 shares at $19.43 ($62,331)
- 4 Open-market sale COFO and Secretary sold 9,972 shares at $19.43 ($193,756)
- 4 Open-market sale President and CEO sold 17,483 shares at $19.43 ($339,695)
- 4 Grant or award COFO and Secretary acquired 53,720 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 53,720 shares (grant or award)
- 4 Grant or award President and CEO acquired 89,520 shares (grant or award)
- 4 Planned sale Director sold 1,666 shares at $23.39 ($38,968)
- 4 Planned sale Director sold 1,666 shares at $19.13 ($31,871)
- 4 Planned sale Director sold 1,666 shares at $20.66 ($34,420)
- 4 Planned sale Director sold 1,666 shares at an average $23.62 ($39,348)
Page 5 of 22 · 436 filings